Close menu




December 15th, 2025 | 07:00 CET

Alibaba, Power Metallic Mines, Bayer – Spectacular twists

  • Mining
  • Commodities
  • PGEs
  • Nickel
  • ecommerce
  • Pharma
Photo credits: pixabay.com

The 2025 stock market year is drawing to a close, and the major indices are likely to finish in positive territory once again. Nevertheless, fears of a correction are growing, especially for hyped AI stocks. In addition, due to sector rotation, there are companies that could stage a year-end rally due to their favorable valuations. Stock picking is likely to be more in demand than ever in the coming months.

time to read: 4 minutes | Author: Stefan Feulner
ISIN: ALIBABA GR.HLDG SP.ADR 8 | US01609W1027 , POWER METALLIC MINES INC. | CA73929R1055 , BAYER AG NA O.N. | DE000BAY0017

Table of contents:


    Bayer – Brightening chart picture

    The crisis-ridden agricultural and pharmaceutical company continues to bottom out. After a consolidation phase lasting more than 10 years and a loss of over 87% to EUR 18.41, Bayer shares have risen significantly since November last year. They are now trading at EUR 30.60, just shy of breaking through the significant resistance level at EUR 31. A sustained break above this level would offer the share short-term upside potential to around EUR 41.

    The Leverkusen-based company received fundamental tailwind from positive Phase 3 results for the anticoagulant Asundexian, which was able to significantly reduce the risk of stroke in patients after a non-cardioembolic ischemic stroke. The once-daily drug Asundexian, in combination with antiplatelet therapy, achieved both primary efficacy and safety endpoints. The US Food and Drug Administration (FDA) has already granted the drug fast-track status.

    Bayer's head of research, Christian Rommel, spoke of an "important milestone" in the Company's commitment to innovative thrombosis prevention. Bayer now plans to hold talks with global authorities and intends to present detailed study data at a scientific congress.

    Analysts view Bayer's development positively. Goldman Sachs is maintaining its "Buy" rating and sets the target price at EUR 34.50. Analyst James Quigley calls the new data "groundbreaking" and estimates the market potential of Asundexian at around EUR 3 billion. JPMorgan, on the other hand, remains more cautious and continues to rate Bayer as "Neutral" with a price target of EUR 25. Although it sees blockbuster potential, comparative data on the competing drug Milvexian is needed to assess the market opportunities accurately.

    Power Metallic Mines – Polymetallic powerhouse with XXL potential

    The global race for strategic metals is picking up speed, and Power Metallic Mines, a Canadian exploration stock, is coming into focus as a future heavyweight in the commodities sector. The combination of high-grade discoveries, an enormous land position, and geopolitical relevance could make the Company one of the most exciting stocks in the North American commodities sector.

    Quebec is one of the world's best jurisdictions for sustainable mining. There, Power Metallic is securing a project portfolio that is rare in the junior sector in terms of size and quality. The NISK project is delivering drill results that are already reminiscent of some of the largest polymetallic discoveries of the past decades. Copper equivalent grades of up to 16% over several meters demonstrate the potential that lies in the ground here. And the 100,000-meter drill program ensures a steady flow of news.

    Meanwhile, the project area is expanding rapidly. Through acquisitions, the property has been increased by over 600% to 313 sq km. Notably, sellers such as Li-FT Power accepted payment in shares, which demonstrates confidence in the management and the quality of the project. At the same time, metallurgical tests are underway at SGS Canada, which have so far confirmed robust sulfide mineralization and, therefore, good conditions for conventional processing methods.

    The geopolitical situation further increases the project's attractiveness. Western industries are looking for independent sources of metal, while China is tightening its export policy. A diversified copper-nickel-PGE project in a secure constitutional state such as Canada is therefore of considerable strategic importance.

    Analysts see enormous catch-up potential. At a current price of CAD 0.92, multiplication potential is forecast. Roth Capital Partners recommends the stock as a "Buy" and sees a 12-month price target of CAD 3.00, while Red Cloud assigns a price target of CAD 2.50.

    Alibaba – AI app impresses

    Since the release of NVIDIA's figures last week, AI stocks have corrected sharply in some cases, and fears of a bubble forming are rife. A look at the sometimes ludicrous valuations shows that these concerns are justified. The situation is different for AI-related companies from China, which, on the one hand, still have exorbitant catch-up potential compared to their US peers, and on the other hand, can shine with fundamental surprises.

    The newly launched Qwen app, the centerpiece of the group's AI strategy, was downloaded over 10 million times in just one week.

    Qwen's rapid rise joins the list of fast-growing AI applications. While ChatGPT set a record pace three years ago and Meta's Threads gained millions of users thanks to Facebook and Instagram, Qwen is now setting new standards, especially in China. The market in China is particularly important for Alibaba, as ChatGPT is not available there.

    The downloads were communicated via WeChat after the Company bundled and modernized its existing apps for iOS and Android under the Qwen brand. Analysts see the spread as a decisive factor for Alibaba's future valuation. In the coming months, Qwen is to be expanded into a fully-fledged AI agent – including shopping integration via Taobao, maps, food delivery, travel bookings, office tools, e-commerce, education, and health services. Group CEO Eddie Wu aims to transform Alibaba into an AI-centric tech giant.


    The Bayer share continues to work on a long-term bottom. Alibaba scored a surprise success with the launch of the Qwen app. Several analysts see significant multiplication potential in Power Metallic Mines.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Fabian Lorenz on December 15th, 2025 | 07:25 CET

    Alarm bells ringing at Evotec! BioNTech and Vidac Pharma achieve success in the fight against cancer! Analysts recommend buying!

    • Biotechnology
    • Biotech
    • Cancer
    • Pharma

    Alarm bells are ringing at Evotec. A major shareholder has completely withdrawn from the German biotech company. The security is trading at 2016 levels. Vidac Pharma, on the other hand, has reached a milestone. In the EU, the Phase 2b clinical trial for the ointment Tuvatexib (VDA1102) against a particularly active, fast-growing precursor of skin cancer can begin. BioNTech is also continuing the fight against cancer. Initial results from the global Phase 2 trial of the non-specific antibody candidate Pumitamig showed encouraging anti-tumor activity in advanced triple-negative breast cancer. Analysts recommend buying shares in Vidac and BioNTech.

    Read

    Commented by Stefan Feulner on December 15th, 2025 | 07:20 CET

    Canopy Growth, American Atomics, Palantir – Energy and cannabis with powerful potential

    • Mining
    • Uranium
    • Software
    • Cannabis
    • Energy

    The end of the week spoiled a positive weekly performance for the stock markets due to disappointing figures from software group Oracle. High-flying AI stocks in particular took a significant hit, as Oracle's AI offerings fell short of analysts' forecasts. In contrast, cannabis stocks soared once again, driven by statements from US President Donald Trump.

    Read

    Commented by André Will-Laudien on December 15th, 2025 | 07:15 CET

    Gold, AI, and Bitcoin – A record year in 2026? Strategy, B2Gold, Kobo Resources, and Allied Gold

    • Mining
    • Gold
    • Commodities
    • Bitcoin
    • crypto

    In mid-December, investors are keeping a close eye on the coming year 2026. Will the old winners also be the new ones? Bitcoin was a disappointment in 2025, as the cryptocurrency is actually down slightly to date. Artificial intelligence and sought-after high-tech suppliers were the focus of attention, with returns of several hundred percent, with Palantir and quantum computing specialist D-Wave, for example, achieving extreme performance. But how will things proceed next year? The majority of analysts believe that the highest-valued high-tech segment will cool down. The primary focus is on NVIDIA, which, with a 1,250% increase since 2021, is now one of the most expensive stocks in the world. The outlook is challenging, as a significant correction or even a crash would also be long overdue. Gold has gained over 60% in the last 12 months, and the trend is fully intact. Could it soon reach USD 5,000?

    Read